A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF OPEVESOSTAT VERSUS ALTERNATIVE ABIRATERONE ACETATE OR ENZALUTAMIDE IN PARTICIPANTS WITH METASTATIC CASTRATIONRESISTANT PROSTATE CANCER (MCRPC) THAT PROGRESSED ON OR AFTER PRIOR TREATMENT WITH ONE NEXT- GENERATION HORMONAL AGENT (NHA) (OMAHA-004)
- Registry ID
- MK-5684-004
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- MERCK CANADA INC
- Start date
- 2026-03-19
- Last update
- 2024-11-21
Conditions
- PROSTATE CANCER
- PROSTATE CANCER METASTATIC CASTRATION RESISTANT
Related clinical trials
- A PHASE III, MULTICENTRE, RANDOMISED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AZD2265 (FPI-2265) 225AC-PSMA-I&T COMPARED WITH STANDARD OF CARE IN PATIENTS WITH PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (VECTRA-01)
- A PHASE I/II OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF AZD6621, A T -CELL-ENGAGING ANTIBODY THAT TARGETS STEAP2, CD3, AND CD8 IN ADULT PARTICIPANTS WITH METASTATIC PROSTATE CANCER (ACTIVATED-4-PC)
- Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
- A PHASE 3, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF XALURITAMIG PLUS ABIRATERONE VERSUS INVESTIGATOR’S CHOICE IN PARTICIPANTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- A PHASE 1/2 FIRST-TIME-IN-HUMAN, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE OPTIMIZATION STUDY OF GSK5471713 IN ADULT PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
- A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF PASRITAMIG (JNJ-78278343), A T-CELL-REDIRECTING AGENT TARGETING HUMAN KALLIKREIN 2, WITH DOCETAXEL VERSUS DOCETAXEL FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
View on source registry